The company said it completed the public offerings of 5 tranches of euro-denominated notes it had announced earlier, on February 26, 2025. The offerings were made under Form S-3 registration statement (Reg. No. 333-269836).

1. 01

   The company said it completed the public offerings of 5 tranches of euro-denominated notes it had announced earlier, on February 26, 2025. The offerings were made under Form S-3 registration statement (Reg. No. 333-269836).

2. 02

   The company disclosed that it issued €600,000,000 of 2.700% notes due 2029 and €700,000,000 of 3.050% notes due 2033.

3. 03

   The company disclosed that it issued €1,000,000,000 of 3.350% notes due 2037, €700,000,000 of 3.600% notes due 2045, and €1,000,000,000 of 3.700% notes due 2055.

4. 04

   Johnson & Johnson said it entered into an underwriting agreement on February 19, 2025 with Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC and other underwriters to issue and sell the notes to the underwriters. The agreement incorporates the Underwriting Agreement Standard Provisions (Debt), dated February 18, 2025.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.